The IMSVISUAL Member Meeting was held virtually on Friday, March 4 from 10:00-11:00 am ET. To watch the member meeting, click below.
February 24, 2021
10:30am – 12:00pm PST/ 12:30pm-2:00pm CST / 1:30-3:00pm EST / 6:30-8:00pm GMT / 7:30-9:00pm GMT+1
Please join us for the IMSVISUAL Member Meeting, taking place on February 24, 2021. An agenda for the meeting will be circulated to all registrants once finalized.
If you would like to attend the IMSVISUAL Member Meeting, please register for the meeting and suggest any agenda items through this survey.
It is our pleasure to invite you to our IMSVISUAL symposium at ACTRIMS Forum 2019 (being held in Dallas, Texas, February 28 – March 2), to discuss updates on vision research in multiple sclerosis and related disorders. For the third consecutive year we are fortunate to have secured ACTRIMS as our sponsor.
The symposium, integrated into the ACTRIMS program and CME accredited, will take place on Thursday, February 28th from 12:30pm – 1:45pm. Please see below the confirmed agenda for talks/speakers during the session. This symposium/session is open to all attendees of the ACTRIMS Forum 2019.
I think this will be an exciting symposium with presentations from
several groups representing existing IMSVISUAL member sites from
around the world.
We look forward to seeing you all in Dallas!
IMSVISUAL symposium at the ACTRIMS Forum 2019, Thursday, February 28th
Session Chairs: Laura Balcer, NYU Langone Health and Elena Martínez-Laspiscina, Hospital Clínic de Barcelona
1: “Is there progressive retinal damage in neuromyelitis optica spectrum disorders?”
Friedemann Paul, NeuroCure Clinical Research Center
2: “Smartphone Suite of Visual Tests in Multiple Sclerosis”
Randy Kardon, University of Iowa Health Care
3: “Corneal Confocal Microscopy: “A rapid non-invasive technique to image neurodegeneration”
Ioannis Petropoulos, Weill Cornell Medicine – Qatar
4: “Dynamics of retinal layer atrophy in normal aging and multiple sclerosis”
Elias Sotirchos, Johns Hopkins University
5: “Retinal imaging in EAE for translational neuroprotection studies”
Philipp Albrecht, Heinrich-Heine-Universität Düsseldorf